Tuesday, November 15, 2011  

Presenter

• Rivaroxaban: A broken RECORD or a step forward in the prevention of VTE
  Mary Parker, PharmD, BCPS, AQ Cardiology
  Clinical Pharmacist Specialist, Durham VA
• Magnum PI: Novel therapies for the treatment of HCV Amanda Corbett, PharmD, BCPS, FCCP, AAHIVE
  Clinical Assistant Professor, UNC Eshelman School of Pharmacy
• The philosophy of PLATO: Breaking down the data on ticagrelor
  Abbie Miller, PharmD, BCPS
  Clinical Specialist, Cardiology, University of North Carolina Hospitals
  
  Objectives:

 After attending this seminar, the participant will be able to:

1. Discuss the differential advantages and disadvantages of rivaroxaban and medications conventionally used to prevent venous thromboembolism following total knee or hip replacement
2. Introduce two new anti-HCV protease inhibitors, telaprevir and boceprevir
3. Explain the role of telaprevir and boceprevir in the treatment of HCV infection
4. Interpret existing data to identify the role of ticagrelor in the management of acute coronary syndrome.